| Original language | English (US) |
|---|---|
| Pages (from-to) | e389-e390 |
| Journal | American Journal of Medicine |
| Volume | 131 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2018 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Medicine, Vol. 131, No. 9, 09.2018, p. e389-e390.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - The Reply
AU - Vaduganathan, Muthiah
AU - Pareek, Manan
AU - Qamar, Arman
AU - Pandey, Ambarish
AU - Olsen, Michael H.
AU - Bhatt, Deepak L.
N1 - Funding Information: Disclosures: Drs. Muthiah Vaduganathan and Arman Qamar are supported by the NHLBI T32 postdoctoral training grant (T32HL007604). Dr. Manan Pareek discloses the following relationships – Advisory Board: AstraZeneca; Speaker Honorarium: AstraZeneca. Dr. Michael H. Olsen discloses that he has received a part-time clinical research grant from the Novo Nordisk Foundation. Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; clinical trial steering committee), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda. The other author reports no relationships relevant to the contents of this paper to disclose.
PY - 2018/9
Y1 - 2018/9
UR - http://www.scopus.com/inward/record.url?scp=85053825140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053825140&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2018.05.024
DO - 10.1016/j.amjmed.2018.05.024
M3 - Letter
C2 - 30057182
AN - SCOPUS:85053825140
SN - 0002-9343
VL - 131
SP - e389-e390
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 9
ER -